A Phase 2b, Randomized, Double-blind, Parallel-group, Placebo Controlled, Dose-finding, Multi-center Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis in Patients Who Have Had an Inadequate Response to Methotrexate
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 379
- 试验地点
- 49
- 主要终点
- Trough plasma concentration of ASP015K and metabolite(s)
研究概览
简要总结
The purpose of this study is to evaluate the safety and efficacy of ASP015K in moderate to severe rheumatoid arthritis subjects who are methotrexate-inadequate responders (MTX-IR).
详细描述
Subjects in each treatment group will continue to take their concomitant oral weekly dose of methotrexate (MTX) in addition to daily ASP015K or matching placebo, taken orally with food, daily for 12 weeks after randomization.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject has rheumatoid arthritis (RA) diagnosed according to the 1987 revised ACR criteria for at least 6 months prior to Screening
- •Subject has been treated with oral methotrexate (MTX) for a minimum of 90 days and at a stable dose for 28 days prior to the first dose of study drug
- •≥6 tender/painful joints; ≥6 swollen joints
- •Subject meets the ACR 1991 Revised Criteria for Global Functional Status in RA Class I, II or III at Screening and Baseline
- •Subject's other medication taken for treatment of RA must be stable for at least 28 days prior to start of the study
- •Male and female subjects must be willing to comply with contraception requirements as well as restrictions regarding egg and sperm donation
- •Female subject must not be breastfeeding at Screening or during the study period, and for 60 days after the final study drug administration
- •Subject agrees not to participate in another interventional study while on treatment
排除标准
- •Positive Mycobacterium tuberculosis (TB) test within 90 days of Screening
- •Abnormal chest x-ray indicative of an acute or chronic infectious process or malignancy
- •Receipt of live or live attenuated virus vaccination within 30 days prior to the first dose of study drug
- •Known history of positive test for hepatitis B surface antigen (HBsAg) or hepatitis C antibody or history of a positive test for human immunodeficiency virus (HIV) infection
- •History of any other autoimmune rheumatic disease, other than Sjogren's syndrome
- •Previous history of clinically significant infections or illness (requiring hospitalization or requiring parenteral therapy) within 90 days of the Baseline visit, or a history of any illness that would preclude participation in the study
- •History of any malignancy, except for successfully treated basal or squamous cell carcinoma of the skin or in-situ carcinoma of the cervix
- •Does not meet specified washout criteria for the following RA medications: gold, azathioprine, minocycline, penicillamine, etanercept, certolizumab, adalimumab, golimumab, infliximab, cyclophosphamide, and leflunomide
- •Subject has previously used a non anti-TNF biologic disease-modifying antirheumatic drug (DMARD) (e.g., anakinra, abatacept, rituximab, tocilizumab)
- •Previous intolerance to Janus kinase (JAK) inhibitors
- •Receipt of intra-articular or parenteral corticosteroid within 28 days prior to the first dose of study drug or is currently taking > 30 mg oral morphine (or narcotic equivalent) per day
- •Absolute lymphocyte count (ALC) < 750/mm3
- •Receipt of plasma exchange therapy within 60 days prior to the start of study drug
- •Receipt of any investigational agent within 30 days or 5 half-lives, whichever is longer, prior to first dose of study drug
- •Receipt of medications that are CYP3A substrates with narrow therapeutic range within 14 days prior to first dose of study drug
- •History of heart failure, defined as New York Heart Association (NYHA) grade 3 or greater
- •History of long QT syndrome or prolonged QT interval
- •Any ongoing severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, metabolic, endocrine, pulmonary, cardiac, neurological, or infectious disease, or any ongoing illness which would make the subject unsuitable for the study. This includes stomatitis, gastrointestinal ulcers, or any other condition that would preclude continued treatment with methotrexate
- •Subject has any condition possibly affecting oral absorption (e.g., gastrectomy, other malabsorption syndromes, or clinically significant diabetic gastroenteropathy)
研究组 & 干预措施
ASP015K lowest dose
ASP015K lowest dose daily in addition to concomitant weekly oral methotrexate
干预措施: peficitinib (Drug)
ASP015K lowest dose
ASP015K lowest dose daily in addition to concomitant weekly oral methotrexate
干预措施: methotrexate (Drug)
ASP015K low dose
ASP015K low dose daily in addition to concomitant weekly oral methotrexate
干预措施: peficitinib (Drug)
ASP015K low dose
ASP015K low dose daily in addition to concomitant weekly oral methotrexate
干预措施: methotrexate (Drug)
ASP015K medium dose
ASP015K medium dose daily in addition to concomitant weekly oral methotrexate
干预措施: peficitinib (Drug)
ASP015K medium dose
ASP015K medium dose daily in addition to concomitant weekly oral methotrexate
干预措施: methotrexate (Drug)
ASP015K high dose
ASP015K high dose daily in addition to concomitant weekly oral methotrexate
干预措施: peficitinib (Drug)
ASP015K high dose
ASP015K high dose daily in addition to concomitant weekly oral methotrexate
干预措施: methotrexate (Drug)
Placebo
Placebo daily in addition to concomitant weekly oral methotrexate
干预措施: Placebo (Drug)
Placebo
Placebo daily in addition to concomitant weekly oral methotrexate
干预措施: methotrexate (Drug)
结局指标
主要结局
Trough plasma concentration of ASP015K and metabolite(s)
时间窗: up to Week 12
Percentage of subjects achieving American College of Rheumatology Criteria 20 (ACR 20) response
时间窗: Week 12
次要结局
- Percentage of subjects achieving ACR 50 response(Week 12)
- Percentage of subjects achieving ACR 70 response(Week 12)
- Change from baseline in Disease Activity Score using 28 joint count and C Reactive Protein (DAS28-CRP)(Baseline and Week 12)